retatrutide triple agonist phase 2 obesity trial Agonism Based Therapies for | Current Cardiovascular Risk Reports Eli Lilly's retatrutide shows promising

Description

January 15, 2026: Wegovy Weight Loss Medication Now Available as a Pill Previously, Wegovy patients received an injectable version of Wegovy to help them manage their weight, diabetes, and cardiovascular health risks

[DOI] [PubMed] [Google Scholar] 193.Marquez-Meneses J.D., Olaya-Bonilla S.A., Barrera-Carreo S., Tibaduiza-Arvalo L.C., Forero-Crdenas S., Carrillo-Vaca L., Rojas-Rodrguez L.C., Calderon-Ospina C.A., Rodrguez-Quintana J

Available from: /current-events/obesity-drugs 7 Goldman Sachs, 2023

Novo Nordisk offers a similar employer program

Although redressing the BA composition has proved to be beneficial in mouse models, it was unlikely to translate to human pathophysiology, as changes in BA composition in mice hardly reflect similar changes in BA profiles in humans due to the differences in BA composition 41